GlassScriptPhysician profile
Natalie Meckel
NPI 1801567862
$6,478.68
in general payments reported to CMS, 2019-2025
20 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $1,564 · 2023: $1,767 · 2024: $871 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,789.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,266.95 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,216.82 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $742.23 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $673.71 | 2021-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $533.24 | 2022-2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $347.28 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $326.26 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $317.26 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $278.25 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $254.73 | 2022-2025 | |
| Corium, LLC | $171.40 | 2024-2025 | Azstarys |
| Noven Therapeutics, LLC | $93.83 | 2024-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $79.31 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $36.74 | 2023-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $34.85 | 2022-2023 | Rotateq, Gardasil 9, Vaxneuvance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.51 | 2025 | Trintellix |
| Biogen, INC. | $20.01 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $19.25 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $19.15 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Meckel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.